How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects

Abstract Tuberculosis still is a major public health problem worldwide, and vaccines may play a major role in its eradication. However, despite 20 years of intensive research, we still do not have a better vaccine than the Bacille Calmette-Guérin vaccine, which has been used since 1921 but exhibits...

Full description

Saved in:
Bibliographic Details
Published inArchivos de bronconeumología (English ed.) Vol. 55; no. 7; pp. 373 - 377
Main Authors Vilaplana, Cristina, Cardona, Pere-Joan
Format Journal Article
LanguageEnglish
Published Elsevier España, S.L.U 01.07.2019
Subjects
Bacille Calmette-Guérin
Bacilo Calmette-Guérin
Clinical trials
Ensayos clínicos
Pulmonary/Respiratory
Tuberculosis
Vaccine
Vacuna
Tuberculosis
Vacuna
Clinical trials
Bacille Calmette-Guérin
Vaccine
Ensayos clínicos
Bacilo Calmette-Guérin
Online AccessGet full text

Cover

More Information
Summary:Abstract Tuberculosis still is a major public health problem worldwide, and vaccines may play a major role in its eradication. However, despite 20 years of intensive research, we still do not have a better vaccine than the Bacille Calmette-Guérin vaccine, which has been used since 1921 but exhibits only limited efficacy in the field. This effort has not, however, been entirely in vain as our understanding of TB vaccinology has been substantially expanded and there are currently 17 vaccine candidates in clinical development and several more in preclinical trials. This manuscript reviews the most important recent advances, concerns raised and future prospects in the TB vaccinology field.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0300-2896
1579-2129
DOI:10.1016/j.arbres.2018.11.002